AlphAIAlphAI — Financial news for AI agents
wpdh.comSEP 192 min read$ABT

Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement

Abbott Laboratories (ABT) will pay $384 million to settle a lawsuit alleging it failed to maintain safety standards in its baby formula manufacturing facilities from 2018 to 2022, according to New York Attorney General Letitia James. The settlement includes $348 million to the federal government and $35 million to a coalition of states, with New York receiving $9.3 million. The lawsuit claimed Abbott's practices put products at risk of contamination and misled safety inspectors.

Original reporting
wpdh.com
Published Sep 19, 2026, 1:12 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 19, 2026, 1:44 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott Laboratories Pays 384 Million In Baby Formula Safety Settlement — source image
Source · wpdh.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The settlement may trigger a short‑term price decline and increase regulatory scrutiny across the infant‑nutrition sector.

02

Market read

A major legal settlement for a large‑cap health‑care firm, introducing financial and reputational risk.

03

What to watch

Abbott's strong cash flow and pipeline in diagnostics may cushion the financial hit; insurance recoveries could reduce net outlay.

Relevance 8/10Novelty 8/10Timing: this week

Background

Abbott Laboratories faced a multi‑state lawsuit alleging unsafe baby‑formula production, leading to a $384 million settlement.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories disclosed a $384 million settlement over baby‑formula safety allegations.

Expected impact

short‑term downside pressure; potential sell‑off as investors reassess risk.

Evidence & confidence

Large cash outflow and negative publicity for a large‑cap health‑care company typically depresses valuation.

Market effects

Sector

May raise scrutiny on other infant‑nutrition firms and could trigger broader sector risk reassessment.

Regional

Potential impact on U.S. consumer‑goods sentiment, especially in health‑care and consumer staples.

Global

Highlights regulatory risk in the global baby‑formula market, possibly affecting multinational suppliers.

Counterpoint

What could challenge this read

The settlement could be viewed as a one‑off cost, with Abbott's diversified portfolio offsetting long‑term impact.

Key entities

  • company
    Abbott Laboratories

    U.S. health‑care company settling the lawsuit.

  • government_official
    Letitia James

    New York Attorney General leading the settlement.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 18
$ABTHighAI 9/10

Why Wall Street Is Becoming Even More Bullish About This Dividend King

Abbott Laboratories (NYSE: ABT) reported Q2 2026 sales of $12.6B, up 13%, and raised its full-year adjusted EPS forecast to $5.45-$5.60. Analysts are bullish, citing growth in its Medical Devices segment and recent acquisitions. The stock has 21 'buy' ratings with target prices up to $143. Abbott's dividend history and growth prospects are key attractions for investors.

theglobeandmail.com3 min
SEP 18
$ABTLowAI 8/10

Abbott to pay $385 million over Michigan baby formula recall that fueled 2022 shortage

Abbott Laboratories agreed to a $385 million settlement over its 2022 recall of baby formula from its Michigan plant, which exacerbated a nationwide shortage. The settlement resolves claims from the DOJ, relators, and state attorneys general. Abbott denies fault or liability. The plant was closed due to contamination concerns but reopened by June 2022. The Biden administration took emergency measures to address the shortage.

finance.yahoo.com2 min
SEP 17
$ABTMedAI 8/10

Attorney General James Secures Over $9 Million for New York from Abbott Laboratories for Manufacturing Potentially Unsafe Baby Formula

New York Attorney General Letitia James announced a settlement with Abbott Laboratories, where the company will pay over $384 million for alleged safety violations in its baby formula products. Abbott is accused of failing to maintain safety standards from 2018 to 2022, leading to potential contamination and misuse of Medicaid and WIC funds. New York will receive over $9.3 million from the settlement.

longisland.com2 min
SEP 17
$ABTMedAI 8/10

Abbott Must Pay $384M for 2022 Contaminated Baby Formula: Who Gets the Payout

Abbott Laboratories agreed to pay $385M to settle allegations of selling contaminated infant formula to government programs, contributing to the 2022 formula crisis. The settlement resolves False Claims Act allegations but does not establish a consumer claims process. The Justice Department emphasized the importance of adhering to health and safety standards for infant formula.

newsweek.com6 min